Year |
Citation |
Score |
2016 |
Barrera LA, Vedenko A, Kurland JV, Rogers JM, Gisselbrecht SS, Rossin EJ, Woodard J, Mariani L, Kock KH, Inukai S, Siggers T, Shokri L, Gordân R, Sahni N, Cotsapas C, et al. Survey of variation in human transcription factors reveals prevalent DNA binding changes. Science (New York, N.Y.). 351: 1450-4. PMID 27013732 DOI: 10.1126/Science.Aad2257 |
0.434 |
|
2016 |
Phadke T, Bothmer A, Lee C, Abdulkerim H, Barrera L, Moss S, Jayaram H, Cotta-Ramusino C. 576. DNA Ends Matter: The Impact of Using CRISPR/Cas9 Variants on DNA Repair Pathway Choices and Editing Profiles at the HBB Locus Molecular Therapy. 24. DOI: 10.1016/S1525-0016(16)33384-6 |
0.301 |
|
2015 |
Rogers JM, Barrera LA, Reyon D, Sander JD, Kellis M, Joung JK, Bulyk ML. Context influences on TALE-DNA binding revealed by quantitative profiling. Nature Communications. 6: 7440. PMID 26067805 DOI: 10.1038/Ncomms8440 |
0.424 |
|
2014 |
Zhao B, Barrera LA, Ersing I, Willox B, Schmidt SC, Greenfeld H, Zhou H, Mollo SB, Shi TT, Takasaki K, Jiang S, Cahir-McFarland E, Kellis M, Bulyk ML, Kieff E, et al. The NF-κB genomic landscape in lymphoblastoid B cells. Cell Reports. 8: 1595-606. PMID 25159142 DOI: 10.1016/J.Celrep.2014.07.037 |
0.392 |
|
2011 |
Tomatsu S, Montaño AM, Oikawa H, Smith M, Barrera L, Chinen Y, Thacker MM, Mackenzie WG, Suzuki Y, Orii T. Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment. Current Pharmaceutical Biotechnology. 12: 931-45. PMID 21506915 DOI: 10.2174/138920111795542615 |
0.306 |
|
Show low-probability matches. |